Drugs & Therapy Perspectives

, Volume 27, Issue 2, pp 5–8 | Cite as

Eltrombopag: a guide to its use in chronic immune (idiopathic) thrombocytopenic purpura

Drug and Profile Report
  • 28 Downloads

References

  1. 1.
    Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 2009 Mar 12; 113(11): 2386–93PubMedCrossRefGoogle Scholar
  2. 2.
    Stasi R, Evangelista ML, Amadori S. Novel thrombopoietic agents: a review of their use in idiopathic thrombocytopenic purpura. Drugs 2008; 68(7): 901–12PubMedCrossRefGoogle Scholar
  3. 3.
    Newland A. Thrombopoietin mimetic agents in the management of immune thrombocytopenic purpura. Semin Hematol 2007 Oct; 44(4 Suppl. 5): S35–45PubMedCrossRefGoogle Scholar
  4. 4.
    Revolade (eltrombopag film-coated tablets): summary of product information. London: European Medicines Agency, 2010Google Scholar
  5. 5.
    Promacta® (eltrombopag): US prescribing information. Research Triangle Park (NC): GlaxoSmithKline, 2009Google Scholar
  6. 6.
    Erickson-Miller CL, Delorme E, Tian SS, et al. Preclinical activity of eltrombopag (SB-497115), an oral, non-peptide thrombopoietin receptor agonist. Stem Cells 2009; 27: 424–30PubMedCrossRefGoogle Scholar
  7. 7.
    Bussel J, Provan D, Shamsi T, et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. Lancet 2009 Feb 21; 373(9664): 641–8PubMedCrossRefGoogle Scholar
  8. 8.
    Bussel J, Psaila B, Saleh M, et al. Efficacy and safety of repeated intermittent treatment with eltrombopag in patients with chronic idiopathic thrombocytopenic purpura [abstract no. 3431]. Blood 2008; 112(11): 1176Google Scholar
  9. 9.
    Cheng G, Saleh MN, Marcher C, et al. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet. Epub 2010 Aug 23Google Scholar
  10. 10.
    Saleh MN, Bussel JB, Cheng G, et al. Long-term treatment of chronic immune thrombocytopenic purpura with oral eltrombopag: results from the EXTEND study [abstract no. 682]. Blood 2009; 114(12): 1326Google Scholar
  11. 11.
    Bussel JB, Cheng G, Saleh MN, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med 2007 Nov 29; 357(22): 2237–47PubMedCrossRefGoogle Scholar
  12. 12.
    Bussel JB, McHutchison J, Provan D, et al. Safety of eltrombopag, an oral non-peptide platelet growth factor, in the treatment of thrombocytopenia: results of four randomized, placebo-controlled studies [abstract no. 1299]. Blood 2007; 110(11): 391aGoogle Scholar
  13. 13.
    Garnock-Jones KP, Keam SJ. Eltrombopag. Drugs 2009; 69(5): 567–76PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2011

Personalised recommendations